A new drug treatment shows promise in treating dysmenorrhea

Primary tabs

A new drug treatment shows promise in treating dysmenorrhea

Scientists described the discovery of a new drug, designed to specifically target the main cause of painful menstrual cramps, not just the symptoms. This condition is called dysmenorrhea, is a common problem which is leading cause of absenteeism from school and work among women.

Menstrual cramps are caused due to uterus contractions during menstruation. In dysmenorrhea, the uterus contracts with increased frequency, causing unusually severe, cramping pain. Scientists believe, is increased blood levels of the hormone vasopressin plays a role in regulating contraction of the uterus.

Martin A et al conducted a double-blind, randomized and pacebo-controlled trial to evaluate the efficacy and safety of an ultra-low-dose oral contraceptive (NPC-01; 0.02 mg ethinyl estradiol and 1 mg norethisterone) in women with dysmenorrhea. They enrolled 250 participants with dysmenorrhea. Patients were randomly assigned to receive NPC-01, placebo, or IKH-01 (0.035 mg ethinyl estradiol and 1 mg norethisterone) for four cycles. The pain was assessed with verbal rating scale (total dysmenorrhea score) and  visual analog scale (VAS) score on the basis of limited ability to work and need for analgesics.

After the treatment, significant higher reductions were noticed in NPC-01 group, as compared to placebo group. Additionally, NPC-01 is efficious as compared to IKH-01. All side effects that occurred in the NPC-01 group were previously reported in patients receiving IKH-01. However, no serious adverse events were reported during the study.

The drug NPC-01 provides a more effective treatment option for millions of women worldwide with this painful condition as this drug relieved dysmenorrhea as effectively as IKH-01. The drug shows promise for sufferers of the debilitating disease and NPC-01 is set to become a new option for long-term treatment of dysmenorrhea.


Fertility and sterility

Link to the source:


Original title of article:

Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial


Andrew Martin

Fertility and sterility
Therapeutic, Ethinyl estradiol, Norethisterone, Dysmenorrhea, Pelvis, Lower Abdomen, Estrogen, Progestin, Placebo-controlled, Double-blind, Randomized Trial, Efficacy, Safety
Log in or register to post comments